{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-112729","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2024-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.798472+00:00","generated_at":"2026-05-30T20:16:55.214266+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Trevi Therapeutics updates pipeline timelines: CORAL at 50% enrolled, SSRE in Dec, RIVER topline Q1 2025","bullets":["Phase 2b CORAL trial for chronic cough in IPF enrolled 50% of target (N=160); SSRE expected December 2024.","SSRE may maintain current size, upsize within pre-specified range, or evaluate for futility; topline H1 2025 if unchanged.","Human Abuse Potential study completed dosing; topline results expected December 2024.","Phase 2a RIVER trial for refractory chronic cough enrolled planned sample size; topline results now expected Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-112729","json":"https://secwatch.observer/filing/0000950170-24-112729.json","markdown":"https://secwatch.observer/filing/0000950170-24-112729.md","text":"https://secwatch.observer/filing/0000950170-24-112729.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024112729/0000950170-24-112729-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024112729/trvi-20241003.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T20:16:55.214266+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}